Research and Development Status
Per 10-Q, the following table summarizes the stages of development for each of our current Product Prospects.
Target Indication Collaborator Status
Multiple Myeloma Sheba Entered into a research agreement for in vitro studies agreement for in vitro studies
Negotiating terms of a Academic research agreement for in vivo studies
Medical Center Completed one in vitro study
Proceeding with further pre-
clinical in vitro studies
(safety and toxicity,
pharmacokinetic, and
pharmacodynamic)
Expect to submit a clinical
trial protocol to the Israeli
Institutional Review Board and
receive its approval to commence
a clinical study.
Intend to commence a clinical
study in the third quarter of
2017
Drafted a clinical trial
protocol synopsis, which we
believe will assist us in
preparing an application for
orphan status designation
Psoriasis Sheba Academic Medical Center
Entered into a Research Collaboration and License Agreement but have not commenced any studies to date
Received an IRB approval for a Phase I, double blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers. The study began in April 2017.
Psoriasis Emilia Cosmetics Ltd. Entered into a
nonbinding memorandum of
understanding for the
development, manufacture and
marketing of a cannabinoid-based
topical cream.
We finished the development of the topical cream in the first quarter of 2016.
Fibromyalgia Sheba Drafted a clinical trial
protocol synopsis.
New delivery system - cannabis soluble tablet
G.C. Group Ltd. Completed a proof of concept (the R=Research phase) of the desired end product (the soluble tablet) to test the fabric, durability, solidification and other features of the cannabis soluble tablet.
